Regulation FD Disclosure. On July 2, 2026, the Company issued a press release announcing the closing of the Merger Agreement, the Name Change and symbol change. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this

Entry into a Material Definitive Agreement. On June 11, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Nomad Transportable Power Systems, Inc (“NOMAD”) and NBD Merger Sub, Inc., (“Merger Sub”), entered into a Merger Agreement (the “Merger Agreement”), pursuant to which Merger Sub is to be merged with and into NOMAD, with NOMAD surviving as a wholly-owned subsidiary of the Company (the “Merger”). On June 30, 2026, the Company, Merger Sub and NOMAD entered into Amendment No. 1 to Me…

Completion of Acquisition or Disposition of Assets. On July 1, 2026, the Merger was consummated by the filing of a Certificate of Merger filed with the Secretary of State of the State of Delaware (the “Effective Time”). At the Effective Time of the Merger, each share of NOMAD common stock outstanding immediately prior to the Effective Time (other than dissenting shares and shares held by unaccredited stockholders) converted into the right to receive a pro rata portion of (i) up to 50,500 shar…

Unregistered Sales of Equity Securities. The information set forth under

Director — John Travaglini: The company appointed John Travaglini to the Board of Directors.

Entry into a Material Definitive Agreement. As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 16, 2026, Lixte Biotechnology Holdings, Inc. (the “ Company ”) entered into a Merger Agreement, dated as of June 11, 2026 (the “ Merger Agreement ”), with NOMAD Transportable Power Systems, Inc. (“ NOMAD ”) and NBD Merger Sub, Inc. (“ NBD Merger Sub ”), pursuant to which NBD Merger Sub will merge with and into NOMAD, with NOMAD survivin…

Entry into a Material Definitive Agreement. On June 11, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Nomad Transportable Power Systems, Inc (“Nomad”) and NBD Merger Sub, Inc., (“Merger Sub”), entered into a Merger Agreement (the Merger Agreement), pursuant to which Merger Sub will merge with and into NOMAD, with NOMAD surviving as a wholly-owned subsidiary of the Company (the “ Merger ” ). At the Effective Time (as defined in the Merger Agreement) of the Merger, each share of NO…

Unregistered Sales of Equity Securities. The information set forth under

Entry Into a Material Definitive Agreement On June 2, 2026, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 2,366,503 shares (the “Common Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common Stoc…

Director — Stuart D. Porter: Appointment of Stuart D. Porter as a member of the Board.

The company replaced stock options with restricted share units for certain officers and directors.

The CEO's annual base salary was increased.

Entry into a Material Definitive Agreement. On March 6, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Liora Technologies Europe Ltd, a subsidiary of the Company (“Liora”) and Orbit Capital Inc., (“Orbit”), entered into an Amended and Restated Share Exchange Agreement with an effective date of November 21, 2025 (the A&R Agreement). The A&R Agreement amends and restates certain terms of the Share Exchange Agreement entered into among the Company, Liora and Orbit Capital on November…

Entry into a Material Definitive Agreement. On February 12, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Liora Technologies Europe Ltd, a subsidiary of Company (“Liora”) and Sidney Bruan (the “Consultant”), entered into an Allocation Deed Agreement (the “Deed”). In conjunction with the Deed, on February 13, 2026, the Company, Liora and the Consultant entered into a Consultancy Agreement (the “Consultancy Agreement”). Pursuant to the Consultancy Agreement, the Consultant will be…

Unregistered Sales of Equity Securities. The disclosure set forth above in

of this Form 8-K relating to exchange of the Series C Shares for Common Stock to Orbit pursuant to the Agreement, is incorporated by reference herein in its entirety. The exchange of the Common Stock to be issued in connection with the exchange of the Series C Shares pursuant to the Agreement was made in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933 (the “Securities Act”), as amended and/or Rule 506 of Regulation D of the Securities A…

Regulation FD Disclosure On December 23, 2025, the Company issued a press release announcing it is expanding its collaboration with The University of Texas MD Anderson Cancer Center, Northwestern University, and pharmaceutical manufacturer GSK on an ongoing clinical trial with its proprietary compound, LB-100, to treat ovarian clear cell cancer. A copy of the press release is furnished herewith as Exhibit 99.1. The information in this

Entry Into a Material Definitive Agreement On December 17, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into Amendment No.2 (“Amendment No.2”) to the GSK & LIXTE Supported Collaborative Study (the “Collaborative Study”) by and between the Company, GlaxoSmithKline LLC (“GSK”) and the University of Texas M.D. Anderson Cancer Center, a government agency of the State of Texas and a member of the University of Texas System (the “Anderson Cancer Center”)…

Termination of a Material Definitive Agreement On December 16, 2025, the Company and Orbit Capital Inc., a Cayman Islands Corporation (the “Royalty Holder”) entered into a termination letter (“Termination Letter”), whereby the Company and the Royalty Holder terminated that certain Royalty Agreement dated November 24, 2025 (the “Royalty Agreement”). Pursuant to the terms of the Royalty Agreement, the Company agreed to pay the Royalty Holder a royalty based on revenues derived from the Company…

Entry Into a Material Definitive Agreement On December 18, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”) 526,342 shares (the “Common Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common St…

Entry Into a Material Definitive Agreement The information set forth in

Completion of Acquisition or Disposition of Assets Share Exchange Agreement On November 21, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “ Company ”), entered into a Share Exchange Agreement (the “ Share Exchange Agreement ”) with Orbit Capital Inc., a Cayman Islands corporation (the “ Seller ”), and Liora Technologies Europe Ltd., a corporation organized under the laws of England and Wales which is wholly-owned by the Seller (the “ Liora ”). Pursuant to the Share Exc…

in its entirety. The Series C Preferred Stock has not been registered under the Securities Act and has been issued in reliance on an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) thereof. The Series C Preferred Stock may not be offered or sold in the United States in the absence of an effective registration statement or exemption from applicable registration requirements. No statement in this document or the attached exhibits is an offer to pur…

Director/President/Vice President and Chief Financial Officer — Rene Bernards, Regina Brown, Bas van der Baan, Robert Weingarten: Multiple senior executives resigned from their positions.

Chief Medical Officer — Dr. Jan Schellens: Dr. Jan Schellens resigned to pursue other employment opportunities.